Calcineurin B subunit triggers innate immunity and acts as a novel Engerix-B ® HBV vaccine adjuvant

Vaccine

Volumn 30, Issue 32, 2012, Pages 4719-4727

  Hu, Minling ^a   Su, Zhenyi ^a   Yin, Yanxia ^a   Li, Jing ^a   Wei, Qun ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Adjuvant; Calcineurin B subunit; HBV vaccine; Integrin M

Indexed keywords

CALCINEURIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 6; RECOMBINANT HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD11B; CALCINEURIN; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B VACCINES; IMMUNITY, INNATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; PROTEIN SUBUNITS; SPLEEN; VACCINES, SYNTHETIC;

EID: 84862522295     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.040     Document Type: Article

References (58)

1. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-125.
2. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8(February (2)):235-247.
3. Adjuvanted hepatitis B vaccine: new drug. Patients with renal failure: similar response rate but fewer boosters needed. Prescrire Int 2008, 17(December (98)):234-236.
4. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002, 20(November (31-32)):3644-3649.
5. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl.):S63-S68.
6. Ott G., Barchfeld G.L., Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995, 13(November (16)):1557-1562.
7. Hem S.L., White J.L. Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 1995, 6:249-276.
8. Pearse M.J., Drane D. ISCOMATRIX adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(January (3)):465-474.
9. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308(March-April (5958)):457-460.
10. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001, 1(3):273-286.
11. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
12. ® HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24(6):693-701.
13. Tong N.K., Beran J., Kee S.A., Miguel J.L., Sanchez C., Bayas J.M., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68(November (5)):2298-2303.
14. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(November (10)):6186-6197.
15. Davis H.L., Weeranta R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998, 160(2):870.
16. Davis H.L., Suparto I., Weeratna R., Iskandriati D., Chamzah S., Ma'ruf A., et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000, 18(18):1920-1924.
17. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20(1):709-760.
18. Rusnak F., Mertz P. Calcineurin: form and function. Physiol Rev 2000, 80(4):1483.
19. Aramburu J., Rao A., Klee C.B. Calcineurin: from structure to function. Curr Top Cell Regul 2001, 36:237-295.
20. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992, 89(9):3686.
21. Clipstone N.A., Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357(6380):695-697.
22. Neilson J.R., Winslow M.M., Hur E.M., Crabtree G.R. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 2004, 20(3):255-266.
23. Liu L., Su Z., Xin S., Cheng J., Li J., Xu L., et al. The calcineurin B subunit (CnB) is a new ligand of integrin αM that mediates CnB-induced Apo2L/TRAIL expression in macrophages. J Immunol 2012, 188(1):238-247.
24. Su Z., Xin S., Xu L., Cheng J., Guo J., Li L., et al. The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-κB pathway in RAW264.7 macrophages. Biochem Biophys Res Commun 2012, 417(January (2)):777-783.
25. Li J., Guo J.X., Su Z.Y., Hu M.L., Liu W., Wei Q. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant. Int Immunol 2011, 23(5):327.
26. Li J., Hu M.L., Guo J.X., Su Z.Y., Wei Q. Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection. Immunol Lett 2011, 140(1-2):52-58.
27. Arnaout M.A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990, 75(5):1037.
28. Larson R.S., Springer T.A. Structure and function of leukocyte integrins. Immunol Rev 1990, 114(1):181-217.
29. Corbi A., Kishimoto T., Miller L., Springer T. The human leukocyte adhesion glycoprotein Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation to the integrins, von Willebrand factor and factor B. J Biol Chem 1988, 263(25):12403.
30. McFarland H.I., Nahill S.R., Maciaszek J.W., Welsh R.M. CD11b (Mac-1): a marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol 1992, 149(4):1326.
31. Rezzonico R., Imbert V., Chicheportiche R., Dayer J.M. Ligation of CD11b and CD11c β2 integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1α (MIP-1α) and MIP-1α production in primary human monocytes through a pathway dependent on nuclear factor κB. Blood 2001, 97(10):2932.
32. Rubel C., Gomez S., Fernandez G.C., Isturiz M.A., Caama o J., Palermo M.S. Fibrinogen-CD11b/CD18 interaction activates the NF-κB pathway and delays apoptosis in human neutrophils. Eur J Immunol 2003, 33(5):1429-1438.
33. Mojadadi S., Jamali A., Khansarinejad B., Soleimanjahi H., Bamdad T. Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice. Cell Mol Immunol 2009, 6(April (2)):111-116.
34. Hao S., Zhao J., Zhou J., Zhao S., Hu Y., Hou Y. Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors. Int Immunopharmacol 2007, 7(December (13)):1765-1775.
35. Weeratna R.D., Makinen S.R., McCluskie M.J., Davis H.L. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005, 23(45):5263-5270.
36. Petersson M., Charo J., Salazar-Onfray F., Noffz G., Mohaupt M., Qin Z., et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998, 161(September (5)):2099-2105.
37. Liu L.X., Su Z.Y., Xin S., Cheng J.B., Li J., Xu L., et al. The calcineurin B subunit (CnB) is a new ligand of integrin αM that mediates CnB induced-Apo2L/TRAIL expression in macrophages. J Immunol 2012, 188(January (1)):238-247.
38. Chow Y.H., Chiang B.L., Lee Y.L., Chi W.K., Lin W.C., Chen Y.T., et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998, 160(February (3)):1320-1329.
39. Kajikawa A., Igimi S. Innate and acquired immune responses induced by recombinant Lactobacillus casei displaying flagellin-fusion antigen on the cell-surface. Vaccine 2010, 28(April (19)):3409-3415.
40. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91(October (3)):295-298.
41. Takeuchi O., Akira S. Pathogen recognition by innate immunity. Arerugi 2007, 56(June (6)):558-562.
42. Bell E. TWEAK and TNF: Yin and Yang in innate immunity. Nat Rev Immunol 2006, 6(2):91.
43. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14(June (6)):705-714.
44. Kaplanski G., Marin V., Montero-Julian F., Mantovani A., Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003, 24(January (1)):25-29.
45. Hirano T., Taga T., Nakano N., Yasukawa K., Kashiwamura S., Shimizu K., et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985, 82(16):5490.
46. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75(2):163-189.
47. Bonjardim C.A. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses-and viruses counteract IFN action. Microb Infect 2005, 7(3):569-578.
48. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13(1):251-276.
49. Curtsinger J.M., Schmidt C.S., Mondino A., Lins D.C., Kedl R.M., Jenkins M.K., et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999, 162(March (6)):3256-3262.
50. Medzhitov R., Janeway C.A. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997, 9(February (1)):4-9.
51. Hoebe K., Janssen E., Beutler B. The interface between innate and adaptive immunity. Nat Immunol 2004, 5(10):971-974.
52. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., Suparto I., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164(3):1617.
53. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(March (3)):179-190.
54. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(July (7)):505-517.
55. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004, 64(August (16)):5850-5860.
56. Wang S., Liu X., Caulfield M.J. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine 2003, 21(October (27-30)):4297-4306.
57. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998, 161(9):4463-4466.
58. Wei Q., Lian M.L., Jing F.Z., Zhang N., Yan M.S., Chen Y., et al. Studies of calcineurin B subunit from genetic engineering for use in medicine. Drug Dev Res 2002, 56(1):40-43.